CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionPrice-to-book is 0.45×, lower than 95% of its Biotechnology peers (median 2.97×)
- FinancialsAltman Z-Score 0.72: distress zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
30.42BINR319.46M · vs all stocks (USD)
Trailing P/E
31.19xvs Biotechnology peers
Revenue (TTM)
29.32BINR307.94M · vs all stocks (USD)
Profit Margin
3.32%vs Biotechnology peers
Beta
0.6210xvs all stocks
52-Week Change
-25.26%vs all stocks
Market Capitalization
30.42BINR319.46M · vs all stocks (USD)
Enterprise Value
50.88BINR534.40M · vs all stocks (USD)
Trailing P/E
31.19xvs Biotechnology peers
Forward P/E
11.14xvs Biotechnology peers
PEG Ratio
0.0858xvs Biotechnology peers
Price to Sales (TTM)
1.04xvs Biotechnology peers
Price to Book (MRQ)
0.4544xvs Biotechnology peers
Enterprise to Revenue
1.74xvs Biotechnology peers
Enterprise to EBITDA
8.99xvs Biotechnology peers
Gross Margin
84.15%vs Biotechnology peers
Profit Margin
3.32%vs Biotechnology peers
Operating Margin
8.71%vs Biotechnology peers
Return on Assets (TTM)
1.29%vs Biotechnology peers
Return on Equity (TTM)
1.56%vs Biotechnology peers
Revenue (TTM)
29.32BINR307.94M · vs all stocks (USD)
Revenue per Share (TTM)
187.14INRUpdated Jul 17, 2026Quarterly Revenue Growth
18.90%vs Biotechnology peers
Gross Profit (TTM)
25.23BINR265.00M · vs all stocks (USD)
EBITDA (TTM)
6.25BINR65.67M · vs all stocks (USD)
Net Income (TTM)
974.50MINR10.24M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-49.50%vs Biotechnology peers
Operating Cash Flow (TTM)
4.91BINR51.62M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
309.45MINR3.25M · vs all stocks (USD)
5-Year Average Dividend Yield
0.98%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
29.32BINRFY2026 · Mar 31, 2026Cost of Goods Sold
4.09BINRFY2026 · Mar 31, 2026Gross Profit
25.23BINRFY2026 · Mar 31, 2026Operating Income
2.27BINR23.84M · vs all stocks (USD)
Pre-tax Income
1.05BINRFY2026 · Mar 31, 2026Income Tax Expense
74.50MINRFY2026 · Mar 31, 2026Net Income
974.50MINRFY2026 · Mar 31, 2026EBIT
2.79BINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
6.22BINRFY2026 · Mar 31, 2026Other Operating Expenses
5.11BINRFY2026 · Mar 31, 2026Non-operating Interest Expense
1.74BINRFY2026 · Mar 31, 2026Minority Interests (P&L)
0.00INRFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
1.06BINRFY2026 · Mar 31, 2026Free Cash Flow
-1.60BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
7.88BINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
1.05BINRFY2026 · Mar 31, 2026Other Non-cash Items
1.59BINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
292.10MINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-1.87BINRFY2026 · Mar 31, 2026Capital Expenditures
-2.67BINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-2.67BINRFY2026 · Mar 31, 2026Long-term Debt Issuance
6.81BINRFY2026 · Mar 31, 2026Long-term Debt Payments
-3.76BINRFY2026 · Mar 31, 2026Net Short-term Debt Issuance
1.01BINRFY2026 · Mar 31, 2026Net Financing Cash Flow
4.07BINRFY2026 · Mar 31, 2026Shares Outstanding
156.78MSharesUpdated Jul 17, 2026Float Shares
55.00MSharesUpdated Jul 17, 2026% Held by Insiders
69.30%vs all stocks
% Held by Institutions
2.69%vs all stocks
Total Cash (MRQ)
10.07BINR105.81M · vs all stocks (USD)
Total Cash per Share (MRQ)
64.41INRUpdated Jul 17, 2026Total Debt (MRQ)
30.76BINR323.08M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4607xvs Biotechnology peers
Current Ratio (MRQ)
1.23xvs Biotechnology peers
Book Value per Share (MRQ)
426.90INRUpdated Jul 17, 2026Total Assets
119.23BINR1.25B · vs all stocks (USD)
Total Current Assets
28.42BINRFY2026 · Mar 31, 2026Total Liabilities
52.46BINRFY2026 · Mar 31, 2026Total Non-current Assets
90.81BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
29.29BINRFY2026 · Mar 31, 2026Total Current Liabilities
23.17BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
7.88BINRFY2026 · Mar 31, 2026Other Short-term Investments
2.43BINRFY2026 · Mar 31, 2026Accounts Receivable
6.73BINRFY2026 · Mar 31, 2026Inventory
10.19BINRFY2026 · Mar 31, 2026Accounts Payable
2.11BINRFY2026 · Mar 31, 2026Short-term Debt
13.18BINRFY2026 · Mar 31, 2026Other Current Liabilities
3.36BINRFY2026 · Mar 31, 2026Long-term Debt
17.58BINRFY2026 · Mar 31, 2026Other Non-current Liabilities
7.03BINRFY2026 · Mar 31, 2026Common Stock (Book)
313.60MINRFY2026 · Mar 31, 2026Total Shareholders' Equity
66.77BINR701.27M · vs all stocks (USD)
52-Week Low
129.00INRUpdated Jul 17, 202652-Week High
321.15INRUpdated Jul 17, 202652-Week Change
-25.26%vs all stocks
Beta
0.6210xvs all stocks
50-Day MA
187.00INRUpdated Jul 17, 2026200-Day MA
211.44INRUpdated Jul 17, 2026Avg 10-Day Volume
39.01KSharesUpdated Jul 17, 2026Avg 30-Day Volume
30.89KSharesUpdated Jul 17, 2026Diluted EPS (TTM)
6.22INRUpdated Jul 17, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 0.45×, lower than 95% of its Biotechnology peers (median 2.97×)Notable
Price-to-book: 0.45Industry median: 2.97Industry P5: 1.03Peers compared: 261
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.84Profit Margin: 0.03
Financial Health
Altman Z-Score 0.72: distress zoneCritical
Altman Z-Score: 0.72
Low earnings qualitySignificant
Earnings Quality Score: -3.86
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Tellgen Corporation
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Shapuaisi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Golden Throat Holdings Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shin Poong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Santhera Pharmaceuticals Holding AG
Tier 1ProductionApproval-Gated PipelineRuleRisk
Medy-Tox Inc.
Tier 1ProductionApproval-Gated PipelineRule
Animalcare Group Plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
Allgens Medical Technology Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Eledon Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Guiyang Xintian Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
adidas AG
1 interpretationIndustry-Benchmarked ROA and Margin Elevated
Ligachem Biosciences Inc.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated
Sun TV Network Ltd.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated